导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.39% | 1629/4773 |
| 近一周 | -1.19% | 1790/5465 |
| 近一月 | -8.20% | 4823/5421 |
| 近一季 | -18.12% | 4692/5231 |
| 近半年 | -0.82% | 1595/4920 |
| 近一年 | 7.28% | 1494/4394 |
| 近两年 | 106.40% | 583/2954 |
| 近三年 | 64.06% | 424/2253 |
| 成立以来 | 117.92% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.89% 2005/4961 |
34.26% 960/5312 |
- - |
- - |
| 2025 | 47.61% 563/4813 |
-1.62% 2713/3635 |
2.98% 1221/4076 |
47.16% 483/4524 |
-0.99% 2767/4813 |
| 2024 | 13.01% 1189/3463 |
-3.45% 1503/2808 |
-6.04% 1836/3014 |
26.43% 261/3129 |
-1.48% 1717/3463 |
| 2023 | -16.82% 1700/2656 |
1.85% 1500/2280 |
-6.45% 1643/2385 |
-8.16% 1670/2515 |
-4.94% 1216/2655 |
| 2022 | -26.14% 1373/2207 |
-18.01% 1290/1919 |
5.63% 857/2016 |
-16.53% 1467/2113 |
2.18% 1018/2208 |
| 2021 | 13.88% 348/1822 |
-5.30% 913/1255 |
25.04% 100/1330 |
-5.86% 870/1466 |
2.16% 678/1822 |
| 2020 | 62.59% 114/1250 |
4.07% 90/1028 |
27.83% 124/1067 |
7.14% 801/1164 |
14.08% 299/1184 |
| 2019 | 39.70% 274/1092 |
31.63% 194/739 |
-9.38% 650/788 |
6.73% 116/850 |
9.73% 202/918 |
| 2018 | - - |
- - |
- - |
-11.09% 564/660 |
-10.26% 184/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 建信创业板ETF联接A VS. 长安沪深300非周期A(740101) |